I aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma. I aim to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic.

As the interim medical co-director of the Stanford Cancer Center, it is my privilege to partner with my colleagues in advancing innovative research alongside high quality, coordinated, and compassionate care for our patients.
Research & Scholarship

CLINICAL TRIALS

- Board Certification: Internal Medicine, American Board of Internal Medicine (2010)

- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma, Recruiting

- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, Not Recruiting

- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy, Not Recruiting

- A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens: (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects # 65 Years With Newly-Diagnosed Acute Myeloid Leukemia, Not Recruiting

- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy, Not Recruiting

- A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome, Not Recruiting

- An Extension Study for Subjects Who Are Deriving Benefit With Idecalisib (GS-1101; CAL-101) Following Completion of a Prior Idecalisib Study, Not Recruiting

- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting

- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting

- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting

- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome, Not Recruiting

- Efficacy and Safety of Idecalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion, Not Recruiting

- Efficacy and Safety Study of Idecalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting

- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting

- Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission, Not Recruiting

- Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL, Not Recruiting

- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma, Not Recruiting

- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting

- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting

- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia, Not Recruiting

- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting

- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting

- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Not Recruiting

- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting

- Safety and Efficacy Study of Pracinostat With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting

- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL, Not Recruiting

- Study to Investigate Idecalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting
Publications

PUBLICATIONS

- **Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3, and MPL mutations.** *Blood advances*
  2022

- **Machine Learning Predictability of Clinical Next Generation Sequencing for Hematologic Malignancies to Guide High-Value Precision Medicine.** *AMIA Symposium proceedings. AMIA Symposium*
  2021; 2021: 641-650

- **A Case of G6PC3 Congenital Neutropenia, Misdiagnosed As Evans Syndrome**
  Camacho, J., Brar, R., Chapman, C., Fernandez-Pol, S., Weinacht, K., Gernez, Y.
  SPRINGER/PLENUM PUBLISHERS.2020: S131–S132

- **Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.** *Surgery open science*
  Alobuia, W. M., Perrone, K. n., Iberri, D. J., Brar, R. S., Spain, D. A., Forrester, J. D.
  2020; 2 (4): 19–24

- **Late presentation of dyskeratosis congenita.** *British journal of haematology*
  Shomali, W., Brar, R.
  2019

- **A Kindred with a #Globin Base Substitution [#89(F5)Ser#Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.** *Hemoglobin*
  2019: 1–4